Philadelphia is home to biotechnology companies, pharmaceutical teams, diagnostic developers, academic medical centers, and translational researchers working on complex questions in therapeutics, diagnostics, immunology, oncology, and related areas of life science. Many of these programs depend on antibodies that must do more than simply bind a target. They need to perform reliably in the specific assay, research workflow, diagnostic format, or development program for which they were created.
At Precision Antibody, we approach custom antibody development with that end use in mind.
We support Philadelphia biopharma and research teams with custom monoclonal antibody development, antibody characterization, binding analysis, epitope evaluation, candidate selection, and related services. Our goal is to help researchers move from an antigen or development objective toward antibody candidates that can be evaluated according to the scientific requirements of the intended application.
Our laboratory operations are based in Columbia, Maryland. We serve organizations in Philadelphia and other life sciences markets without representing that we maintain a physical Philadelphia laboratory or office.
For biotechnology, pharmaceutical, diagnostic, and academic teams that need specialized antibody support, this approach provides a practical way to combine development and characterization within a coordinated scientific workflow.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there?
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
A custom antibody project begins with a scientific objective, not with a standard laboratory sequence applied to every target.
The antigen, intended application, screening approach, species, desired antibody properties, and downstream use can all affect how a development program should be structured. For that reason, we design projects around the purpose the antibody ultimately needs to serve.
For Philadelphia teams developing diagnostic assays, therapeutic research programs, research tools, or translational applications, this can help align development decisions with the performance criteria that matter later.
One of the most important distinctions in custom monoclonal antibody development is the difference between finding an antibody that recognizes an antigen and finding an antibody that works in the required application.
Those are not always the same outcome.
An antibody may bind strongly under one experimental condition yet perform poorly in another. Assay format, antigen presentation, target conformation, sample type, epitope accessibility, affinity, and kinetic behavior can all influence practical performance.
Our development approach considers these factors early so that screening can be designed around the actual project objective wherever possible.
A typical program may involve:
Defining the intended application and scientific requirements.
Selecting or preparing an appropriate antigen.
Developing an immunization strategy.
Generating antibody producing hybridomas.
Screening candidates using relevant criteria.
Performing single cell cloning.
Characterizing promising antibody candidates.
Selecting clones for downstream use, sequencing, production, or additional testing.
This integrated view helps connect early development decisions with later antibody performance.
Precision Antibody develops custom mouse and rat monoclonal antibodies for a variety of research, diagnostic, and therapeutic research needs.
Species selection can depend on several project specific factors, including antigen characteristics, immune response considerations, intended downstream use, and the broader development strategy. Rather than treating species as an isolated choice, we consider it within the full project context.
For applicable custom monoclonal antibody programs, our stated development timelines may be approximately 40 to 60 days. Actual timelines can vary according to project design, antigen behavior, screening requirements, and the level of characterization needed.
The focus remains on producing useful candidates while maintaining a development process that supports practical scientific decision making.
Different applications create different expectations for antibody performance.
A diagnostic development team may need antibodies that work as a reliable pair in a sandwich format. A therapeutic research program may care more about affinity, specificity, epitope behavior, or functional properties. A research group may need a monoclonal that recognizes a particular form of a target under a defined laboratory condition.
The development strategy should reflect those differences.
We have experience supporting antibody development for applications that can include:
• ELISA
• Sandwich ELISA
• Lateral flow
• Flow cytometry
• Immunohistochemistry
• Other application specific assay formats
For diagnostic work, screening strategy is especially important because the strongest binder is not automatically the best assay antibody. Pair compatibility, accessible epitopes, target presentation, background behavior, and assay conditions can affect performance.
Therapeutic research programs often require more extensive evaluation of promising candidates.
Depending on the project, researchers may need to understand:
• Binding strength
• Association and dissociation behavior
• Epitope relationships
• Candidate diversity
• Sequence information
• Functional performance
• Suitability for further development
By integrating antibody development with characterization, teams can gather more relevant information before deciding which clones warrant additional investment.
Antibody characterization helps researchers understand what a candidate does, how it interacts with its target, and whether its properties support the next stage of a program.
It can include analysis of affinity, binding kinetics, isotype, molecular characteristics, epitope behavior, sequence, oligomeric state, and other project specific attributes.
Our antibody characterization services are designed to provide scientific information that can support candidate comparison, screening decisions, assay development, and downstream planning.
Characterization is especially valuable when several antibodies appear promising and the development team needs a rational basis for selecting among them.
Affinity describes the overall strength of interaction between an antibody and its antigen. Binding kinetics provide additional information by examining how quickly the antibody associates with the target and how quickly the complex dissociates.
These measurements can help distinguish antibodies that may appear similar in a simpler binding assay.
For example, two candidates could show comparable apparent binding under one screening condition while having meaningfully different association or dissociation behavior.
That difference may matter for the intended application.
Binding analysis can support:
• Candidate ranking
• Comparison of antibody target interactions
• Evaluation of binding strength
• Analysis of association and dissociation behavior
• Selection of antibodies for further development
• Investigation of project specific binding questions
Affinity is an important parameter, but it should not always be interpreted in isolation. The best candidate depends on the scientific objective.
Precision Antibody uses Biacore and Octet platforms for label free binding analysis.
These technologies provide ways to examine molecular interactions without relying on a fluorescent or enzymatic label attached to the analyte solely for detection.
Biacore and Octet based analysis can be used for activities such as:
• Confirmatory antibody screening
• Antibody quantification
• Affinity ranking
• Binding kinetics
• Epitope binning
• Antibody pairing
• Custom interaction studies
The appropriate platform and assay format depend on the sample, target, project stage, and type of information needed.
For a Philadelphia biotechnology team comparing several promising monoclonal antibodies, the value is not simply having access to an instrument. The more important question is how the resulting data will help guide the project.
That may mean determining which candidates bind more strongly, identifying antibodies with distinct interaction profiles, or selecting clones for further functional testing.
Binding behavior is only one part of antibody characterization.
Biochemical and molecular analysis can provide additional information about the identity and properties of selected clones.
Antibody isotyping identifies the immunoglobulin class or subclass associated with a monoclonal antibody. This information can be relevant to purification, assay design, reagent selection, and downstream development.
Sequence analysis can provide the molecular definition of a selected antibody clone.
Precision Antibody capabilities include variable heavy and variable light chain sequencing and related cloning services. VH and VL sequence information can be useful when a program moves beyond hybridoma based production or when researchers need a defined molecular record of a selected monoclonal.
Analytical size exclusion chromatography can be used to examine antibody samples for oligomeric or aggregate related behavior.
This type of information may be relevant when researchers need a broader biochemical understanding of an antibody candidate.
Depending on project requirements, characterization can also include custom assays designed around questions that are not fully addressed by a standard testing panel.
The value of these services lies in assembling the right information for the decision at hand rather than generating data simply because a method is available.
Antibodies can recognize the same target while interacting with different regions of that target.
Understanding those differences can be important in diagnostic development, candidate selection, antibody pairing, and broader research programs.
Epitope analysis helps researchers examine how antibody candidates relate to one another and to the target they recognize.
An epitope is the region of an antigen that is recognized by an antibody.
Epitope mapping broadly refers to methods used to investigate where or how an antibody interacts with its target. Depending on the approach, the goal may be to identify a specific region, characterize relative binding behavior, or distinguish candidates that recognize different antigenic sites.
This information can be useful when researchers need more than a simple positive or negative binding result.
For example, a program may need to determine whether several antibodies all recognize a similar region or whether the panel contains candidates with more diverse epitope behavior.
Epitope binning groups antibodies according to their competitive binding relationships.
If two antibodies interfere with one another’s binding, they may recognize overlapping or spatially related epitopes. If they can bind without meaningful competition under the assay conditions, they may recognize different accessible regions.
Epitope binning can help researchers:
• Organize a large antibody panel
• Identify groups with similar competition behavior
• Find candidates that recognize nonoverlapping epitopes
• Evaluate diversity within an antibody collection
• Support antibody pairing decisions
• Prioritize candidates for additional testing
The result is not simply a set of bins. It is a more structured view of how the antibody panel behaves.
Sandwich immunoassays typically require two antibodies that can engage the target in a compatible manner.
One antibody captures the target, while another detects it.
If the antibodies compete strongly for the same or overlapping binding site, they may not function well as a pair. Candidates that recognize distinct accessible epitopes can therefore be valuable when identifying potential capture and detection combinations.
Epitope binning and antibody pairing studies can help narrow a larger panel to combinations worth evaluating in the intended assay.
This is particularly relevant for diagnostic developers in Philadelphia working on ELISA based platforms or other immunoassay formats where pair compatibility is fundamental to performance.
A well designed antibody program should connect each stage of development to the decision that follows it.
Rather than viewing antigen preparation, monoclonal generation, screening, characterization, and candidate selection as disconnected services, we approach them as parts of a continuous process.
The first question should be practical:
What does the antibody ultimately need to do?
The answer may affect antigen selection, screening conditions, assay design, characterization priorities, and candidate selection.
A monoclonal intended for flow cytometry may need to recognize a native cell surface target. An antibody intended for a sandwich assay may need to work in combination with a second antibody. A therapeutic research candidate may require more detailed analysis of binding behavior and epitope relationships.
Defining that objective early provides direction for the rest of the project.
Once the intended use is clear, the project can be structured around the antigen, species, immunization approach, screening strategy, and required milestones.
Not every antibody project benefits from the same workflow.
A customized strategy can help ensure that development decisions reflect the biology of the target and the requirements of the final application.
After immunization and hybridoma development, screening is used to identify promising antibody producing clones.
The quality of this stage depends heavily on what is being measured.
A screening assay should be selected with the intended application in mind wherever possible. Otherwise, a project can favor candidates that look strong in an early assay but later prove less useful under real application conditions.
Promising antibodies can then be examined in greater detail.
Characterization may include affinity ranking, kinetic analysis, isotyping, epitope binning, antibody pairing, sequencing, analytical SEC, or other project relevant methods.
These data help researchers understand how candidates differ.
The final choice should be driven by the complete project objective.
In some programs, the highest affinity antibody may be the preferred candidate. In others, epitope behavior, pair compatibility, functional performance, sequence, or assay specific characteristics may matter more.
The purpose of characterization is to make that decision more informed.
Philadelphia’s life sciences community includes organizations working across biotechnology, pharmaceuticals, diagnostics, academic research, translational science, and emerging therapeutic areas.
Not every team needs to maintain a complete internal antibody development and characterization operation.
Outsourcing can provide access to specialized capabilities while allowing internal scientists to remain focused on their central research or development priorities.
Custom antibody work involves more than producing hybridomas.
Antigen strategy, immunization, screening, cloning, characterization, sequencing, and application testing each require different scientific decisions.
Working with a specialized antibody development group can provide continuity across these stages.
Binding analysis platforms and characterization methods require instrumentation, assay development experience, and dedicated technical resources.
For a biotechnology company that needs these capabilities periodically or at a specific stage of a program, outsourcing can be more practical than developing every method internally.
It also allows teams to access multiple forms of characterization within a coordinated project.
Development schedules can become constrained when internal resources are limited or when several programs compete for the same laboratory capacity.
For applicable projects, our custom monoclonal development process may progress within approximately 40 to 60 days, although the actual schedule depends on project design and scientific requirements.
The goal is not speed at the expense of useful data. It is to move the project forward efficiently while preserving the application specific focus of the development program.
Every candidate that moves downstream consumes time and resources.
Characterization can help teams make better informed decisions before investing in additional production, assay optimization, functional testing, engineering, or other advanced work.
This is particularly important when several candidates initially appear promising.
Philadelphia and the surrounding region support a broad range of life sciences activity, from emerging biotechnology ventures to established pharmaceutical organizations and major academic research institutions.
Precision Antibody works with pharmaceutical, biotechnology, diagnostic, academic, federal, and research customers. That breadth allows us to support different project types while maintaining a specialized focus on antibody development and characterization.
Biotechnology and pharmaceutical teams may require antibody support at multiple points in a program.
Common needs can include:
• New monoclonal generation
• Candidate screening
• Binding analysis
• Affinity ranking
• Epitope evaluation
• Sequence analysis
• Antibody production
• Functional testing support
The most useful workflow depends on the maturity of the program and the scientific decision that needs to be made next.
Diagnostic antibody requirements can be particularly application dependent.
An antibody intended for a sandwich ELISA, lateral flow platform, flow cytometry assay, or IHC workflow must be evaluated within the context of that application.
For sandwich assays, pair compatibility can be especially important. For other diagnostic formats, target presentation, specificity, background, or accessibility may influence performance.
Custom development and characterization can be coordinated around these needs.
Academic researchers and translational teams may encounter targets for which suitable commercial antibodies are unavailable, insufficiently characterized, or not optimized for the intended experiment.
A custom development program can provide a route toward antibodies designed around a particular biological question.
Characterization can then help define which candidates are best suited for continued research.
Our laboratory operations are in Columbia, Maryland, not Philadelphia.
For organizations in Greater Philadelphia, our role is to provide specialized antibody development and characterization support from that facility while working collaboratively with project teams throughout the region.
That distinction matters because local relevance should be based on the customers and scientific programs we serve, not on implying a physical presence that does not exist.
A custom antibody project requires trust in both the science and the process.
Our approach combines decades of antibody development experience with project specific planning, application focused screening, characterization capabilities, and direct support throughout the workflow.
Precision Antibody was founded in 2000 and has worked on several thousand custom antibody projects.
That experience spans a range of pharmaceutical, biotechnology, diagnostic, academic, federal, and research applications.
Experience matters because antibody projects do not always behave predictably. Targets differ, immune responses vary, and the best screening strategy depends on what the antibody needs to accomplish.
Our core philosophy is that an antibody should be evaluated according to the function it must ultimately perform.
That is why application requirements influence how we think about development, screening, characterization, and candidate selection.
A strong binding signal alone does not define success.
Development and characterization can be handled as connected stages.
A candidate generated during a custom program can move into affinity ranking, kinetic analysis, epitope binning, sequencing, or other forms of evaluation as appropriate.
This helps create continuity between antibody generation and the decisions that follow.
Custom antibody development is collaborative.
Project requirements may evolve as new data become available, and scientific questions often arise during screening or characterization.
Dedicated project support helps maintain communication and provides a clear point of contact as the work progresses.
For custom programs, ownership is an important commercial and scientific consideration.
Precision Antibody states that customers own the antibody clones developed for their projects. We do not retain ownership of those developed clones.
That provides organizations with greater control over the antibodies generated for their programs.
Confidentiality is particularly important for pharmaceutical and biotechnology research.
Precision Antibody can work under confidentiality agreements and other appropriate commercial agreements, including CDAs, NDAs, and MSAs.
Project design can also be adapted to the scientific requirements rather than forcing every program into an identical service structure.
Antibody characterization is the process of evaluating important properties of an antibody so researchers can better understand its identity, binding behavior, molecular characteristics, and suitability for an intended use.
Depending on the project, characterization may include affinity measurement, binding kinetics, epitope analysis, isotyping, sequencing, analytical SEC, antibody pairing, and custom assays.
Affinity describes the overall strength of the interaction between an antibody and its target.
Binding kinetics provide more detailed information about the rates of association and dissociation.
Two antibodies can have similar overall affinity while interacting with the target differently over time. For some applications, understanding those kinetic differences can help with candidate selection.
Epitope mapping is a broad term for approaches used to investigate where or how an antibody recognizes its target.
Epitope binning is a comparative method that groups antibodies according to their competitive binding behavior.
In practical terms, mapping seeks information about the antibody’s interaction with the antigen, while binning helps determine how antibodies within a panel relate to one another.
Epitope binning can identify antibodies that appear to recognize nonoverlapping epitopes under the assay conditions.
Those candidates may be useful for antibody pairing studies because two antibodies in a sandwich assay generally need to engage the target without preventing one another from binding.
Binning does not replace assay testing, but it can help prioritize promising combinations.
For applicable Precision Antibody projects, custom mouse or rat monoclonal development may be completed in approximately 40 to 60 days.
The exact timeline depends on factors such as antigen characteristics, immunization response, screening requirements, cloning, characterization, and any additional project specific work.
Yes. Application specific screening is a central part of our approach when an appropriate screening format can be incorporated into the project.
This matters because an antibody that binds well in one test may not perform as required in the final assay or research workflow.
Designing screening around the intended use can improve the relevance of early candidate selection.
Precision Antibody states that customers own the clones generated for their custom projects.
We do not retain ownership of those developed antibody clones.
For biotechnology, pharmaceutical, diagnostic, and research organizations, this provides greater control over the resulting reagents and their future use.
Yes. We support biotechnology, pharmaceutical, diagnostic, academic, and research organizations in Philadelphia and other regions with custom antibody development and characterization services.
Projects can be structured around needs such as monoclonal antibody development, binding analysis, epitope binning, antibody pairing, sequencing, and related characterization.
No. Precision Antibody’s laboratory operations are based in Columbia, Maryland.
We serve organizations in Philadelphia and the broader life sciences community from that location. We do not represent that we maintain a Philadelphia laboratory or office.
The most useful antibody development strategy begins with a clear understanding of what the antibody needs to accomplish.
Whether your Philadelphia team needs a new monoclonal antibody, deeper characterization of existing candidates, affinity and kinetic analysis, epitope binning, antibody pairing, sequencing, or an integrated development workflow, the project should be designed around the scientific decision you ultimately need to make.
At Precision Antibody, we combine custom development, application focused screening, characterization capabilities, and dedicated project support to help biotechnology, pharmaceutical, diagnostic, academic, and research teams move from an antibody idea toward better informed candidate selection.
The next step is to define the target, intended application, current project stage, and the information your team needs most. From there, we can help shape a development or characterization approach that fits the scientific goals of the program.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
